FDA records indicate that there are no current recalls for this drug.
Are you a medical professional?
Trending Topics
Mag-al Plus Xs Recall
Get an alert when a recall is issued.
Questions & Answers
Side Effects & Adverse Reactions
The maximum recommended daily dosage of this product is 60 mL (12 teaspoonfuls). Do not take more than this dosage in a 24-hour period or use this dosage for more than 2 weeks except under the advice and supervision of a physician. Do not use this product except under the advice and supervision of a physician if you have kidney disease. As with any drug, if you are pregnant or nursing a baby, seek the advice of a health professional before using this product.
Prolonged use of aluminum-containing antacids in patients with renal failure may result in or worsen dialysis osteomalacia. Elevated tissue aluminum levels contribute to the development of the dialysis encephalopathy and osteomalacia syndromes. Small amounts of aluminum are absorbed from the gastrointestinal tract and renal excretion of aluminum is impaired in renal failure. Aluminum is not well removed by dialysis because it is bound to albumin and transferrin, which do not cross dialysis membranes. As a result, aluminum is deposited in bone, and dialysis osteomalacia may develop when large amounts of aluminum are ingested orally by patients with impaired renal function.
Aluminum forms insoluble complexes with phosphate in the gastrointestinal tract, thus decreasing phosphate absorption. Prolonged use of aluminum-containing antacids by normophosphatemic patients may result in hypophosphatemia if phosphate intake is not adequate. In its more severe forms, hypophosphatemia can lead to anorexia, malaise, muscle weakness, and osteomalacia.
KEEP THIS AND ALL DRUGS OUT OF THE REACH OF CHILDREN.
Ask a doctor or pharmacist before use if you are presently taking a prescription drug. Antacids may interact with certain prescription drugs.
Ask a doctor or pharmacist before use if you are presently taking a prescription drug. Antacids may interact with certain prescription drugs.
Legal Issues
There is currently no legal information available for this drug.
FDA Safety Alerts
There are currently no FDA safety alerts available for this drug.
Manufacturer Warnings
There is currently no manufacturer warning information available for this drug.
FDA Labeling Changes
There are currently no FDA labeling changes available for this drug.
Uses
As an antacid for symptomatic relief of hyperacidity associated with the diagnosis of peptic ulcer, gastritis, peptic esophagitis, gastric hyperacidity, or hiatal hernia. As an antiflatulent to alleviate the symptoms of gas, including postoperative gas pain.
History
There is currently no drug history available for this drug.
Other Information
There are no additional details available for this product.
Sources
Mag-al Plus Xs Manufacturers
-
Pharmaceutical Associates, Inc.
-
Cardinal Health
Mag-al Plus Xs | Cardinal Health
Levetiracetam oral solution is indicated as adjunctive treatment of partial onset seizures in adults and children 4 years of age and older with epilepsy.
Levetiracetam oral solution is indicated as adjunctive therapy in the treatment of myoclonic seizures in adults and adolescents 12 years of age and older with juvenile myoclonic epilepsy.
Partial Onset Seizures Adults 16 Years And OlderIn clinical trials, daily doses of 1000 mg, 2000 mg, and 3000 mg, given as twice-daily dosing, were shown to be effective. Although in some studies there was a tendency toward greater response with higher dose (see CLINICAL STUDIES), a consistent increase in response with increased dose has not been shown.
Treatment should be initiated with a daily dose of 1000 mg/day, given as twice-daily dosing (500 mg BID). Additional dosing increments may be given (1000 mg/day additional every 2 weeks) to a maximum recommended daily dose of 3000 mg. Doses greater than 3000 mg/day have been used in open-label studies for periods of 6 months and longer. There is no evidence that doses greater than 3000 mg/day confer additional benefit.
Pediatric Patients Ages 4 To <16 YearsTreatment should be initiated with a daily dose of 20 mg/kg in 2 divided doses (10 mg/kg BID). The daily dose should be increased every 2 weeks by increments of 20 mg/kg to the recommended daily dose of 60 mg/kg (30 mg/kg BID). If a patient cannot tolerate a daily dose of 60 mg/kg, the daily dose may be reduced. In the clinical trial, the mean daily dose was 52 mg/kg. Patients with body weight ≤20 kg should be dosed with oral solution. Patients with body weight above 20 kg can be dosed with either tablets or oral solution. Table 13 below provides a guideline for dosing based on weight during titration to 60 mg/kg/day.
Levetiracetam is given orally with or without food.
Table 13: Levetiracetam Oral Solution Weight-Based Dosing Guide For Children Patient Weight Daily Dose 20 mg/kg/day
(BID dosing) 40 mg/kg/day
(BID dosing) 60 mg/kg/day
(BID dosing)20.1-40 kg
500 mg/day
2.5 mL
BID1000 mg/day
5 mL
BID1500 mg/day
7.5 mL
BID>40 kg
1000 mg/day
5 mL
BID2000 mg/day
10 mL
BID3000 mg/day
15 mL
BIDThe following calculation should be used to determine the appropriate daily dose of oral solution for pediatric patients based on a daily dose of 20 mg/kg/day, 40 mg/kg/day or 60 mg/kg/day:
Total daily dose (mL/day) =
Daily dose (mg/kg/day) × patient weight (kg)
100 mg/mL
A household teaspoon or tablespoon is not an adequate measuring device. It is recommended that a calibrated measuring device be obtained and used. Healthcare providers should recommend a device that can measure and deliver the prescribed dose accurately, and provide instructions for measuring the dosage.
Myoclonic Seizures In Patients 12 Years Of Age And Older With Juvenile Myoclonic EpilepsyTreatment should be initiated with a dose of 1000 mg/day, given as twice-daily dosing (500 mg BID). Dosage should be increased by 1000 mg/day every 2 weeks to the recommended daily dose of 3000 mg. The effectiveness of doses lower than 3000 mg/day has not been studied.
Adult Patients With Impaired Renal FunctionLevetiracetam dosing must be individualized according to the patient's renal function status. Recommended doses and adjustment for dose for adults are shown in Table 14. To use this dosing table, an estimate of the patient's creatinine clearance (CLcr) in mL/min is needed. CLcr in mL/min may be estimated from serum creatinine (mg/dL) determination using the following formula:
CLcr =
[140-age (years)] × weight (kg)
(× 0.85 for female patients)
72 × serum creatinine (mg/dL)
Table 14: Dosing Adjustment Regimen For Adult Patients With Impaired Renal Function Group Creatinine Clearance
(mL/min) Dosage
(mg) Frequency * Following dialysis, a 250 to 500 mg supplemental dose is recommended.Normal
>80
500 to 1,500
Every 12 h
Mild
50 to 80
500 to 1,000
Every 12 h
Moderate
30 to 50
250 to 750
Every 12 h
Severe
<30
250 to 500
Every 12 h
ESRD patients using dialysis
----
500 to 1,000
*Every 24 h
Login To Your Free Account